Introduction: The ICH Q11 CMC drug development guidelines, read together with ICH Q8(R2), explain how sponsors should design, justify and […]
ICH Q11 and Q8 Guidelines in CMC Drug Development: A Practical Overview for Sponsors Read More »
Introduction: Choosing among CMC consulting services for biotech startups comes down to one question: which partner can turn your science
CMC Consulting Services for Biotech Startups: How to Choose the Right CRO Partner Read More »
Introduction Understanding Peptide CDMO Cost / Pricing in the United States involves examining a complex financial landscape in which preclinical
How Much Does Peptide Manufacturing Cost with a US CDMO? Read More »
Introduction Evaluating a contract development and manufacturing organization (CDMO) for peptide active pharmaceutical ingredients (APIs) involves more than assessing conventional
Top Things to Look for in a GMP Peptide CDMO Partner Read More »
Introduction CMC Due Diligence Support involves a comprehensive assessment of the technical, regulatory, and quality aspects of drug substance and
CMC Due Diligence Support for Pharma Licensing Deals and Investor Audits Read More »
Introduction Overcoming Polymorphic Instability During NDA CMC Review requires the implementation of orthogonal solid-state characterization protocols, validation of robust crystallization
Introduction: The CMC requirements 505(b)(2) NDA applicants must satisfy are the same quality standards that apply to any new drug
CMC Requirements for 505(b)(2) NDA Pathway: What Makes It Different from a Full NDA Read More »
Introduction A well-prepared Common Technical Document (CTD) Module 3 serves as a comprehensive, reviewer-ready Chemistry, Manufacturing, and Controls (CMC) quality
Regulatory CMC Writing Services: What a Well-Prepared CTD Module 3 Looks Like Read More »
Introduction Scale-Up and Tech Transfer in CMC represents a critical operational pathway through which bench-scale drug formulation and synthesis are
Introduction FDA expectations for Extractables and Leachables in CMC require pharmaceutical sponsors to demonstrate chemical compatibility through risk-based material characterization,
